GMAB
Genmab AS
34.60$
-3.2%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 1.7% | 2.7% | 4.5% | 3.6% | 4.9% | 5.2% | 5.9% | 6.2% | 5.7% | 7.7% | 7.3% | 7.3% | 7.0% | |
| 98.3% | 97.3% | 95.5% | 96.4% | 95.1% | 94.8% | 94.1% | 93.8% | 94.3% | 92.3% | 92.7% | 92.7% | 93.0% | |
| 44.3% | 41.6% | 55.6% | 46.3% | 41.2% | 41.4% | 50.2% | 39.4% | 34.9% | 49.7% | 49.1% | 39.7% | 43.1% | |
| 17.8% | 20.0% | 142.1% | 114.8% | 15.6% | 19.4% | 119.7% | 15.6% | 14.5% | 19.7% | 18.5% | 17.7% | 17.6% | |
| 62.6% | 61.6% | 76.3% | 66.1% | 57.1% | 61.2% | 67.8% | 54.9% | 49.4% | 69.4% | 67.6% | 57.5% | 60.7% | |
| 35.8% | 35.7% | 19.2% | 30.3% | 37.9% | 33.5% | 26.3% | 38.9% | 44.9% | 23.0% | 25.1% | 35.2% | 32.3% | |
| 0.2% | 0.1% | 0.7% | 2.4% | 0.3% | 0.8% | 0.7% | 1.0% | 0.3% | 4.2% | 12.5% | 9.5% | 6.5% | |
| 56.7% | 19.8% | 41.3% | 39.4% | 31.0% | 55.9% | 34.1% | 45.7% | 47.2% | 5.2% | 8.3% | 25.5% | 21.9% | |
| 12.0% | 6.1% | 9.5% | 13.4% | 8.2% | -3.8% | 6.9% | 9.4% | 7.9% | 2.3% | 2.3% | -0.7% | 2.9% | |
| 44.7% | 13.7% | 31.8% | 26.1% | 22.9% | 59.7% | 27.3% | 36.3% | 39.2% | 2.9% | 5.9% | 26.2% | 19.1% | |
| 58.7% | 21.2% | 44.1% | 41.6% | 39.8% | 36.6% | 37.1% | 48.4% | 49.2% | 9.4% | 20.8% | 37.3% | 29.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.